News

Nasdaq16d
IO Biotech Presents New Preclinical Data Supporting Dual-Antigen and TGF-β-Directed Vaccines for Enhancing Anti-Tumor Immunity at AACR 2025
IO Biotech presents preclinical data supporting dual-antigen and TGF-β-targeted vaccines for enhancing anti-tumor immunity at AACR 2025. IO Biotech presented new preclinical data at the AACR ...
Nasdaq15d
IO Biotech's Co-Founder Mads Hald Andersen Highlights Advances in Cancer Vaccine Research at 2025 AACR Annual Meeting
IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...
Seeking Alpha15d
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...